Gastrointestinal Bleeding in Patients with SARS-CoV-2 Infection Managed by Interventional Radiology.
COVID-19
GIB
embolization
gastrointestinal bleeding
interventional radiology
risk factors
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
17 Oct 2021
17 Oct 2021
Historique:
received:
15
08
2021
revised:
05
10
2021
accepted:
11
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
This study was conducted to evaluate the technical and clinical success of trans-arterial embolization (TAE) as a treatment of gastrointestinal bleeding (GIB) in Coronavirus Disease 2019 (COVID-19) patients and to describe its safety; moreover, we describe the characteristics of these patients. Thirty-four COVID-19 hospitalized patients presented with GIB. Risk factors, drugs administered for COVID-19 infection, and clinical and biological parameters were evaluated. Furthermore, intraprocedural data and outcomes of embolization were analyzed. GIB was more frequent in male. Overweight, hypertension, diabetes, previous cardiac disease, and anticoagulation preadmission (48.5%) were frequently found in our population. Previous or actual COVID Acute respiratory distress syndrome (ARDS) and a high level of D-dimer were encountered in most cases. Upper GIB was more frequent than lower GIB. Technical and clinical success rates of embolization were 88.2% and 94.1%, respectively. The complication rate was 5.9%. Our study highlights the most frequent characteristics of COVID-19 patients with GIB. Embolization is feasible, effective, and safe.
Sections du résumé
BACKGROUND
BACKGROUND
This study was conducted to evaluate the technical and clinical success of trans-arterial embolization (TAE) as a treatment of gastrointestinal bleeding (GIB) in Coronavirus Disease 2019 (COVID-19) patients and to describe its safety; moreover, we describe the characteristics of these patients.
METHODS
METHODS
Thirty-four COVID-19 hospitalized patients presented with GIB. Risk factors, drugs administered for COVID-19 infection, and clinical and biological parameters were evaluated. Furthermore, intraprocedural data and outcomes of embolization were analyzed.
RESULTS
RESULTS
GIB was more frequent in male. Overweight, hypertension, diabetes, previous cardiac disease, and anticoagulation preadmission (48.5%) were frequently found in our population. Previous or actual COVID Acute respiratory distress syndrome (ARDS) and a high level of D-dimer were encountered in most cases. Upper GIB was more frequent than lower GIB. Technical and clinical success rates of embolization were 88.2% and 94.1%, respectively. The complication rate was 5.9%.
CONCLUSIONS
CONCLUSIONS
Our study highlights the most frequent characteristics of COVID-19 patients with GIB. Embolization is feasible, effective, and safe.
Identifiants
pubmed: 34682879
pii: jcm10204758
doi: 10.3390/jcm10204758
pmc: PMC8541615
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Intern Med. 2021 Jun;289(6):887-894
pubmed: 33341978
Front Med (Lausanne). 2021 Mar 09;8:647917
pubmed: 33768106
Am J Gastroenterol. 2016 Apr;111(4):459-74
pubmed: 26925883
J Vasc Interv Radiol. 2017 Oct;28(10):1432-1437.e3
pubmed: 28757285
Semin Thromb Hemost. 2020 Oct;46(7):815-818
pubmed: 32512587
Clin Res Hepatol Gastroenterol. 2021 May;45(3):101521
pubmed: 32888875
Cardiovasc Intervent Radiol. 2020 Jun;43(6):820-826
pubmed: 32277272
BMJ. 2020 Jan 6;368:l6744
pubmed: 31907166
J Am Coll Radiol. 2021 May;18(5S):S139-S152
pubmed: 33958109
Am J Gastroenterol. 2020 Jul 1;115(7):1139-1140
pubmed: 32618672
Thromb Res. 2020 Dec;196:227-230
pubmed: 32916565
Gastrointest Endosc. 2020 Aug;92(2):454-455
pubmed: 32325065
Gut. 2018 Oct;67(10):1757-1768
pubmed: 29691276
Am J Gastroenterol. 2021 Apr;116(4):838-840
pubmed: 33982964
J Thromb Haemost. 2020 Oct;18(10):2629-2635
pubmed: 32692874
Am J Gastroenterol. 2020 Jun;115(6):942-946
pubmed: 32496741
Am J Gastroenterol. 2015 Sep;110(9):1265-87; quiz 1288
pubmed: 26303132
Am J Gastroenterol. 2021 May 1;116(5):899-917
pubmed: 33929377
Aliment Pharmacol Ther. 2020 May;51(9):843-851
pubmed: 32222988
Am J Gastroenterol. 2020 Oct;115(10):1609-1616
pubmed: 32796176
Am J Gastroenterol. 2020 May;115(5):766-773
pubmed: 32287140
Rev Esp Enferm Dig. 2020 May;112(5):383-388
pubmed: 32343593
Am J Gastroenterol. 2020 Aug;115(8):1283-1285
pubmed: 32516204